Combined BRAF and MEK inhibitors, as compared with BRAF inhibitors alone, should be delay the emergence of resistance and should be reduce toxic effects in patients who have melanoma with BRAF V600E or V600K mutations (Long et al., 2014). This evidence concerns the gene MAP2K7 and melanoma.